Sun Yongbing, Ma Wen, Yang Yuanyuan, He Mengxue, Li Aimin, Bai Lei, Yu Bin, Yu Zhiqiang
National Engineering Research Center for solid preparation technology of Chinese Medicines, Jiangxi University of Traditional Chinese Medicines, Nanchang 330006, China.
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Asian J Pharm Sci. 2019 Nov;14(6):581-594. doi: 10.1016/j.ajps.2019.04.005. Epub 2019 Jun 12.
Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. In addition to sorafenib and lenvatinib for the treatment of HCC approved by FDA, various strategies including transarterial chemoembolization, radiotherapy, locoregional therapy and chemotherapy have been investigated in clinics. Recently, cancer nanotechnology has got great attention for the treatment of various cancers including HCC. Both passive and active targetings are progressing at a steady rate. Herein, we describe the lessons learned from pathogenesis of HCC and the understanding of targeted and non-targeted nanoparticles used for the delivery of small molecules, monoclonal antibodies, miRNAs and peptides. Exploring current efficacy is to enhance tumor cell response of chemotherapy. It highlights the opportunities and challenges faced by nanotechnologies in contemporary hepatocellular carcinoma therapy, where personalized medicine is increasingly becoming the mainstay. Overall objective of this review is to enhance our understanding in the design and development of nanotechnology for treatment of HCC.
肝细胞癌（HCC）是最致命的癌症之一，因其具有复杂性、手术切除后复发、转移和异质性。除了美国食品药品监督管理局（FDA）批准的用于治疗HCC的索拉非尼和仑伐替尼外，包括经动脉化疗栓塞、放疗、局部区域治疗和化疗在内的各种策略已在临床上进行了研究。最近，癌症纳米技术在包括HCC在内的各种癌症治疗中受到了极大关注。被动靶向和主动靶向都在稳步发展。在此，我们描述了从HCC发病机制中吸取的经验教训，以及对用于递送小分子、单克隆抗体、微小RNA和肽的靶向和非靶向纳米颗粒的理解。探索当前疗效是为了增强化疗对肿瘤细胞的反应。它突出了纳米技术在当代肝细胞癌治疗中面临的机遇和挑战，其中个性化医疗正日益成为主流。本综述的总体目标是增进我们对用于治疗HCC的纳米技术设计和开发的理解。
